You can still IP protect delivery mechanisms and branding. Insulin and tums are examples, respectively. I don't see what the potential for issues here is unless

You can still IP protect delivery mechanisms and branding. Insulin and tums are examples, respectively. I don't see what the potential for issues here is unless it's an ultra-rare disease where the total market isn't worth the certification costs. That doesn't describe Alzheimer's.